Dr. Judith Feucht studies the further development and improvement of cellular immune therapies, especially with chimeric antigen receptor T-cells (“CAR T-cells”). Her research in the lab of Prof. Michel Sadelain at Memorial Sloan Kettering Cancer Center in New York (USA) and as part of the iFIT Cluster of Excellence at the Children’s Hospital of the University of Tübingen yielded important insights into the therapeutic efficacy of CAR T-cells and thus made a major contribution to the development of a new form of these genetically modified white blood cells. In preclinical studies, these novel CAR T-cells have shown improved therapeutic results and are currently being tested in patients.

For her outstanding research, physician and junior research group leader Dr. Judith Feucht receives the 2021 Friedmund Neumann Prize.